Skip to main content
. 2014 Sep 12;21(4):385–391. doi: 10.1111/cns.12326

Figure 4.

Figure 4

SS‐31 treatment does not reduce the expression of inflammatory markers and brain injury in permanent focal ischemia. (AC) Brain CD36 (A), MCP‐1 (B), and CCR2 (C) mRNA levels in mice treated with saline (veh) or SS‐31 24 h after pMCAO, n = 4/group, ***< 0.001 versus contralateral, Two‐way ANOVA. (D and E) Stroke outcome measurement 3 days after pMCAO. Infarct volume (D) and % swelling (E), n = 9–10/group, NS, nonsignificant.